Clinical trialNACompleted
Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer
- Outcome
- Finished, no results posted
- Phase
- NA
- Status
- Completed
- Study type
- Interventional
- Start
- 1 October 2016
- Expected end
- 1 October 2020
- Enrollment
- 61 participants
- Sites
- 1
- Primary outcomes
- Safety (number of adverse effects)
- Sponsor
- Other
- Results posted
- No
- Last update
- 22 January 2021
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The aim of this study was to compare the therapeutic efficacy between simultaneous gemcitabine administration and IRE and IRE alone for locally advanced pancreatic cancer (LAPC)
Detailed description public domain (ClinicalTrials.gov)
in the GEM- IRE group, before the IRE ablation started, patients received 1000 mg/m2 gemcitabine hydrochloride \[Qilu pharmaceutical (Hainan) Co., Ltd. Haikou, China\] intravenously (over approximately 30 min). In the IRE group, the IRE ablation was performed without gemcitabine intravenous infusion before IRE. The aim of this study was to evslusted the overall survival (OS), objective response rate (ORR) and adverse events after simultaneous therapy.